All Posts By

Motif

Result of General Meeting

By | Announcements
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that at the General Meeting held earlier today all resolutions as set out in the Notice of General Meeting annexed to the circular to shareholders dated 23 June 2015 were duly passed. The passing of the resolutions represents the satisfaction of the first of the two conditions to completion of the conditional placing of 44,000,000 ordinary shares announced by the Company on 23 June 2015. The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied. Enquiries Motif Bio plc Graham Lumsden, Chief Executive Officer Robert Bertoldi, Chief Financial Officer...
Read More

Placing to Raise £22 million, Appointment of Nominated Adviser and Joint Broker and Notice of General Meeting

By | Press Releases
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that the Company has today conditionally placed 44,000,000 new ordinary shares, through Zeus Capital and Northland Capital Partners as joint brokers to the Company, at a placing price of 50p per ordinary share with institutional investors to raise £22 million. View the Placement The Placing is conditional, inter alia, upon: (i) Shareholders approving the Resolutions at the General Meeting to grant to the Directors the authority to allot the Placing Shares and permit the disapplication of statutory pre-emption rights in respect of the allotment of the Placing Shares; and (ii) the successful grant of the QIDP designation for iclaprim in the US...
Read More

Motif Bio Releases Audited Non-statutory Financial Statements for the Year Ended 31 December 2014

By | Press Releases
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, reports to the market today the non-statutory financial statements of its wholly-owned subsidiary, Motif BioSciences, Inc. for the year ended 31 December 2014 - a period prior to the completion of the Company's merger, acquisition, and admission to AIM. Since the end of the period covered by these financial statements, Motif Bio plc has completed the Group re-organisation, a necessity of becoming the holding company of the Group.  Motif has also converted and restructured its liabilities, acquired the iclaprim assets, and raised new funds of approximately US $4.3 million, before issue costs of approximately US $1.0 million, through a placing and subscription of new shares...
Read More

Motif partners with Leading Global CRO for Phase III Clinical Trials with Iclaprim

By | Press Releases
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its wholly-owned subsidiary, Motif BioSciences Inc., has signed Letters of Intent (LOIs) and interim agreements with a leading global Clinical Research Organisation (CRO). Under the terms of these interim agreements, the CRO will undertake preparations for two Phase III, randomised, double-blind, multicenter clinical trials to evaluate the efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections ("ABSSSIs") suspected or confirmed to be due to Gram-positive pathogens. Iclaprim is a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria. Motif is investing over US$950,000 under the terms of the interim agreements, to...
Read More

Motif Receives FDA Meeting Minutes Confirming Iclaprim Phase III Clinical Development Programme

By | Press Releases
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has received the official meeting minutes from the U.S. Food and Drug Administration (FDA) guidance meeting which was held on 14 April 2015. The minutes confirm the FDA's agreement with Motif's Phase III clinical development programme for iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria. Iclaprim, a novel selective inhibitor of microbial dihydrofolate reductase (DHFR), is being developed as an intravenous (IV) formulation to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) caused by Gram positive pathogens, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP)....
Read More

Motif Selected to Present at World’s Largest Biotech Event

By | Announcements
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, announced today that the Company has been selected to present at the 2015 BIO International Convention, the leading global event for the Biotechnology sector. BIO International is the world’s largest biotech meeting, regularly attracting 15,000 of the world’s most powerful biotechnology and pharmaceutical players from 65 countries, offering unparalleled business partnering, education and networking. The convention is to be held in the Pennsylvania Convention Centre, Philadelphia, Pennsylvania, USA, on 15-18 June 2015. Enquiries Motif Bio plc Graham Lumsden, Chief Executive Officer Robert Bertoldi, Chief Financial Officer info@motifbio.com Plumtree Capital Limited (Financial Adviser) Stephen...
Read More

Funding Strategy Update

By | Announcements
The Board of Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today updated investors with its funding strategy following agreement on 14th April 2015 by the U.S. Food and Drug Administration (FDA) with the proposed Phase 3 clinical development programme for the Company's lead product candidate, iclaprim.  The Company anticipates commencing Phase 3 trials in the second half of this year. To fund these trials Motif is continuing to explore available options, including strategic partnerships with other pharmaceutical companies, non-dilutive government funding from grants, and market funding should the valuation of the Company be supportive. The Company is therefore pleased to announce that it has been selected to present at BioEquity Europe 2015. ...
Read More

Motif Gains FDA Agreement to Enter Phase 3 Clinical Development with Iclaprim

By | Press Releases
Iclaprim safety and efficacy to be studied in two serious and life-threatening infections. Motif Bio plc (LSE: MTFB), announced today that the U.S. Food and Drug Administration (FDA) has agreed to the proposed Phase 3 clinical development programme for the Company’s lead product candidate, iclaprim. The Phase 3 programme is designed to obtain marketing approval for an intravenous formulation of iclaprim in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) caused by Gram positive pathogens, including resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). The FDA confirmed that two ABSSSI trials or one ABSSSI trial plus one HABP trial meeting their pre-specified primary endpoints are...
Read More

First Day of Dealings: Clinical stage biopharmaceutical company developing new antibiotics admitted to AIM

By | Press Releases
Motif Bio plc, a clinical stage biopharmaceutical company specialising in the development of antibiotics, is pleased to announce that admission and trading of its Ordinary Shares commences today on AIM with the ticker MTFB. KEY POINTS: The Company has a lead antibiotic candidate, iclaprim, in clinical development. The directors anticipate that iclaprim could be ready for commercialisation within approximately 36 months. The Company is seeking to confirm in meetings with the FDA and EMA in the first half of 2015, that the clinical development plan for iclaprim meets regulatory guidelines and that two Phase III trials can be conducted. A Type C meeting is scheduled with the FDA for 14 April 2015. Resistance to antibiotics is a major global public...
Read More